Uroplasty (UPI) and Obalon Therptcs (OBLN) Critical Contrast

Uroplasty (NYSE: UPI) and Obalon Therptcs (NASDAQ:OBLN) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Institutional & Insider Ownership

45.0% of Obalon Therptcs shares are held by institutional investors. 16.4% of Obalon Therptcs shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Uroplasty and Obalon Therptcs’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Uroplasty N/A N/A N/A N/A N/A
Obalon Therptcs $4.98 million 29.12 -$27.12 million ($6.90) -1.25

Uroplasty has higher revenue, but lower earnings than Obalon Therptcs.

Profitability

This table compares Uroplasty and Obalon Therptcs’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Uroplasty -31.58% -87.33% -60.82%
Obalon Therptcs -566.87% -108.07% -48.50%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Uroplasty and Obalon Therptcs, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Uroplasty 0 0 0 0 N/A
Obalon Therptcs 1 0 3 0 2.50

Obalon Therptcs has a consensus price target of $15.25, suggesting a potential upside of 76.91%. Given Obalon Therptcs’ higher possible upside, analysts clearly believe Obalon Therptcs is more favorable than Uroplasty.

Summary

Obalon Therptcs beats Uroplasty on 6 of the 8 factors compared between the two stocks.

About Uroplasty

Cogentix Medical, Inc. (Cogentix Medical) is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover. The Company’s products include Urgent PC Neuromodulation System, Macroplastique Bulking Agent, Endoscopy Systems and EndoSheath Technology. The Company is also engaged in the commercialization of the Urgent PC Neuromodulation System, a device which delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). Its Macroplastique is an injectable soft-tissue bulking agent used to treat stress urinary incontinence (SUI) due to intrinsic sphincter deficiency (ISD). The Company offers 5000 and 7000 series of endoscopes, which are video endoscopy systems.

About Obalon Therptcs

Obalon Therapeutics, Inc. is a United States-based commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company’s product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients. The Obalon balloon system is intended to be used as an adjunct to a moderate intensity diet and behavior modification program. All balloons must be removed six months after the first balloon is placed. The Obalon balloon system intends to provide patients and physicians with a reversible and repeatable weight loss solution in an outpatient setting, without altering patient anatomy or requiring surgery. The Company has received Premarket approval (PMA) for its Obalon balloon system based on the results of its United States pivotal clinical trial, referred to as the SMART trial.

What are top analysts saying about Uroplasty Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Uroplasty Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit